Preoperative diagnostic categories of fine needle aspiration cytology for histologically proven thyroid follicular adenoma and carcinoma, and Hurthle cell adenoma and carcinoma: Analysis of cause of under- or misdiagnoses

Hee Young Na, Jae Hoon Moon, June Young Choi, Hyeong Won Yu, Woo-Jin Jeong, Yeo Koon Kim, Ji-Young Choe, So Yeon Park

1 Department of Pathology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea, 2 Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea, 3 Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea, 4 Department of Otorhinolaryngology—Head and Neck Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea, 5 Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea, 6 Department of Pathology, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea

* sypmd@snu.ac.kr

Abstract

Cytologic diagnosis of thyroid follicular adenoma and carcinoma, and Hurthle cell adenoma and carcinoma (FACHAC) is challenging due to cytomorphologic features that overlap with other follicular-patterned lesions. This study was designed to analyze diagnostic categories (DCs) of preoperative fine needle aspiration cytology (FNAC) of histologically proven thyroid FACHACs to evaluate under- or misdiagnoses in FNAC and elucidate potential causes for such phenomena. A total of 104 thyroid nodules with preoperative FNAC were included in this study. Of these, 66 cases had also undergone thyroid core needle biopsy (CNB); FNAC and CNB DCs were compared in these cases. Various cytologic and histologic parameters were compared between the nodules with different FNAC DCs. After a review of FNAC slides, DCs were re-assigned in 20 (19.2%) out of the 104 cases. Of the 66 cases with CNB diagnoses which were mostly classified as lower DCs in FNAC, 31 (47.0%) were diagnosed as suspicious for a follicular neoplasm in CNB. Cases which were underdiagnosed in FNACs were associated with lower cellularity, predominant macrofollicular pattern, absence of microfollicles arranged in trabecular pattern, and absence of transgressing vessels in cytology smears. High cellularity, microfollicles arranged in trabecular pattern, nucleolar prominence, and large cell dysplasia were more frequently found in malignancy than in benign neoplasm. In conclusion, thyroid FACHACs seem to be under- and misdiagnosed in preoperative FNAC. Innate characteristics of the nodules were associated with under-diagnosis as well as the quality of the FNAC.
Introduction

Ultrasoundography (USG)-guided fine needle aspiration cytology (FNAC) is the most commonly used preoperative testing method for thyroid nodules. Currently, FNAC results are classified into six diagnostic categories (DCs) according to The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) in most countries [1, 2]. Although thyroid FNAC is diagnostic in a majority of benign nodules as well as in most papillary thyroid carcinomas (PTCs) and other types of carcinomas, it generally functions as a screening test for follicular-patterned lesions. The cytologic findings of follicular adenoma (FA) and carcinoma, and Hurthle cell adenoma (HA) and carcinoma [FACHAC] can significantly overlap with various other thyroid follicular-patterned lesions including nodular hyperplasia, noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), and even follicular variant PTC [3–5]. In addition, a final diagnosis of follicular thyroid carcinoma (FTC) or Hurthle cell carcinoma (HC) can only be made after thorough examination and confirmation of capsular and/or vascular invasion in the resection specimen. Although TBSRTC suggests certain criteria for rendering DC IV (suspicious for a follicular neoplasm; SFN) to identify potential FTCs or HCs and to refer them for diagnostic lobectomy with higher sensitivity rather than higher specificity [1, 2], preoperative cytologic diagnosis of FACHAC remains challenging. The incidence of FTC is much lower than PTC in Korea [6], however, there has been an increase in detection rates of indeterminate nodules through screening USG of the thyroid [6–8]. Since FTC and HC can potentially progress to distant metastasis, it is important not to underdiagnose or misdiagnose these malignancies and prevent the treatment delay in patients with these tumors.

USG-guided thyroid core needle biopsy (CNB) has been continuously reported to be a useful complementary tool for FNAC by reducing non-diagnostic or indeterminate results, especially when the results are reported according to a standardized system [9–12]. Moreover, CNB has been reported to be a more reliable method than FNAC in diagnosing follicular-patterned neoplasm with lower false positive rates, and higher risk of malignancy rates [13–15]. This advantage of CNB over FNAC is attributed to the fact that CNB can provide histologic information including not only the nodule itself, but also its relationship with the capsule and surrounding normal thyroid tissue [13–15].

According to the nationwide survey done by the Korean Society for Cytopathology in 2012, the average rate of TBSRTC DC IV (SFN) was 0.9% (range 0–2.1%) [16], a number much smaller compared to western countries [17]. Thus, in the present study, we reviewed preoperative FNACs of thyroid nodules with final surgical diagnoses of FACHAC to investigate whether there were under- or misdiagnoses in FNAC. In cases in which preoperative CNB had been performed, we compared DCs of FNAC and CNB. Finally, we analyzed various cytologic and histologic features of each nodule and correlated them with FNAC DCs to identify the potential causes of under- or misdiagnoses.

Materials and methods

Cases selection

We collected a total of 11,695 thyroid FNACs from 10,824 patients diagnosed at Seoul National University Bundang Hospital from January 2012 to December 2018. Of 10,824 patients, 270
patients underwent repeated FNACs for the same nodule, and the DC with the highest risk of
malignancy was selected. In 592 patients, multiple nodules were separately aspirated, and they
were considered individual cases. Finally, 11,396 FNAC cases were used for this study. All
FNAC slides were diagnosed according to TBSRTC, 1st or 2nd edition [1, 2].

Of the 11,396 FNACs, a total of 4,369 nodules were surgically resected, yielding 190 (4.3%) cases of FACHAC; 102 (2.3%) FAs, 42 (0.9%) FTCs, 39 (0.9%) HAs, and 7 (0.2%) HCs. Of
these 190 cases, 121 cases had both FNAC and surgical resection slides available. We re-evalu-
ated surgical slides of these 121 cases according to the 2017 WHO classification [18], and 17
cases showing unequivocal nuclear atypia (nuclear score 2 or 3) [19] were re-classified as
PTCs: 2 encapsulated variant PTCs with predominant follicular pattern and 15 invasive encap-
sulated follicular variant PTCs. Finally, a total of 104 cases with final diagnoses of FACHAC
were included in the present study. This study was approved by the Institutional Review Board
(IRB) of Seoul National University Bundang Hospital (IRB No. B-2003-598-301), and the
requirement for informed consent was waived. All the samples used in this study were
obtained from archival material in the Department of Pathology. All the data including patient
record and samples were fully anonymized before we analyzed them.

Ultrasonography and USG-guided FNAC and CNB procedures
Thyroid USG (iU22, Philips Medical Systems, Bothell, WA), USG-guided thyroid FNACs, and
CNBs were performed by one of three board-certified radiologists. FNACs were done using a
22- to 25-gauge needle. CNBs were executed using 18-gauge automatic biopsy needles with a
1.1-cm excursion (TSK Ace-cut; Create Medic, Yokohama, Japan). One to two cores of speci-
men were obtained for each thyroid nodule. As previously described [10], CNBs were per-
formed after considering the size and imaging features of the thyroid nodules including (1)
any suspicious malignant nodule (with any one of the following features: taller than wide
shape, spiculated margin, marked hypoechoicism, microcalcification, or macrocalcification),
over 5 mm; (2) an indeterminate nodule (without probably benign features or suspicious
malignant features), over 10 mm; and (3) a probably benign nodule (isoechoic spongiform
nodule, comet-tail artifact, predominantly cystic) over 20 mm, according to the 2009 ATA
management guidelines [20] and the consensus statement of the Korean Society of Thyroid
Radiology [21].

Review of FNAC
All thyroid FNAC slides were reviewed by two experienced pathologists (SYP and HYN) in a
blind manner. Discordant cases were discussed to reach consensus. The diagnoses were made
according to TBSRTC, 2nd edition [2]. Various cytologic parameters including cellularity, pres-
ence of artifact, architectural pattern, nuclear features, and background quality were analyzed
in FNAC specimens. As for architectural pattern, proportions of macrofollicular- and micro-
follicular patterns were evaluated. In addition, types of architectural alteration reported in FN
and Hurthle cell neoplasm (HN) were analyzed: the presence of architectural crowding,
3-dimensional branching pattern, microfollicles arranged in trabecular pattern, and trans-
gressing vessels (Figs 1 and 2). Of these, “microfollicles arranged in trabecular pattern” was
defined as microfollicles forming 3-dimensional clusters and trabecular arrangement as
described in a previous study by Han et al [22] (Fig 3). Regarding nuclear features, the pres-
ence of nuclear enlargement, anisonucleosis, nuclear hyperchromasia, prominent nucleoli,
small cell or large cell dysplasia, and the presence of PTC-like nuclear atypia was described.
Small cell dysplasia was defined as the cytoplasmic diameter less than twice the nuclear diame-
ter, and large cell dysplasia as the cytoplasmic diameter greater than twice the variation in
nuclear diameter [23] (Fig 2). Presence of background colloid, blood, or cystic change was also recorded. When colloid was present, the type of colloid (thin, thick, and both) was also noted.

**Pathologic review of CNB specimens**

Of the 104 cases, 66 cases were also evaluated by thyroid CNB. The DCs of thyroid CNB were compared with those of FNAC. The diagnosis of CNB was made into one of six DCs based on
the standardized reporting system proposed by the Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group. The six DCs are similar to those of TBSRTC; I. non-diagnostic, II. benign lesion, III. indeterminate lesion, IV. SFN, V. suspicious for malignancy, and VI. malignant. Indeterminate lesion was subdivided into indeterminate lesion with architectural atypia and indeterminate lesion with nuclear atypia. SFN category was subdivided into SFN without nuclear atypia and SFN with nuclear atypia [24]. All thyroid CNB slides were reviewed by two pathologists (SYP and HYN) in a blind manner, and discordant cases were discussed to reach consensus.
Pathologic review of resection specimens

To identify whether the cytologic diagnoses are affected by their histologic features, we analyzed various histologic parameters of tumors in resection specimen: proportion of normo- and macrofollicular pattern, papillary hyperplasia, intratumoral fibrosis, calcification or bony metaplasia, cystic degeneration, hemorrhage, background lymphocytic thyroiditis and tumor size. All resection specimens were also reviewed by two pathologists (SYP and HYN) in a blind manner, and discussion for the discordant cases was performed.

Statistical analyses

Statistical analyses were performed by using SPSS version 22.0 (IBM, NY, USA). To compare the frequencies of categorical variables between two groups, Pearson chi-square test or Fisher’s exact test were applied. All p-values reported were two-sided, and a p-value of less than 0.05 was considered statistically significant.

Results

Preoperative FNAC diagnostic categories of histologically proven FACHAC

The original DCs of 104 FNAC cases were retrieved from the electronic medical records. All slides were carefully reviewed in a blinded fashion. DCs were revised in 20 out of the 104 cases. In the original diagnoses, 18 (17.3%), 13 (12.5%), 63 (60.6%), 7 (6.7%), 2 (1.9%), and 1 (1.0%) were classified as DC I (non-diagnostic), II (benign), III (AUS), IV (SFN), V (suspicious for malignancy), and VI (malignant), respectively (Table 1). After review, 20 (19.2%), 8 (7.7%), 60 (57.7%), and 16 (15.4%) cases were categorized into DC I (non-diagnostic), II (benign), III (AUS), IV (SFN), respectively (Table 2). Detailed cytologic and histologic features of FACHACs included in the current study are summarized in S1 Data.

The summary of 20 cases with revised FNAC diagnoses is shown in Table 3. A total of 12 cases were originally underdiagnosed and were re-diagnosed into higher DCs. Three cases with original DC II (benign) were revised to DC III (AUS) due to the presence of architectural alteration including microfollicles and predominance of Hurthle cells in spite of low cellularity. Nine cases with original DC III (AUS) were re-categorized into DC IV (SFN) since all of these specimens showed at least moderate cellularity with prominent architectural alteration. The original diagnoses of suspicious for PTC and PTC were given in 2 cases and 1 case respectively, which were re-categorized as DC III (AUS) and IV (SFN). Of these 3 cases, 2 cases were proven to be HC. In the remaining one case (case No. 50) with final surgical diagnosis of FA,
3-dimensional branching sheet with focal nuclear enlargement and grooves might have led to the original FNAC DC V (suspicious for PTC) (Fig 4). Nevertheless, the diagnosis was revised to DC III (AUS) based on the moderate cellularity with focal architectural alteration, and the presence of equivocal nuclear atypia in a limited area (Fig 4).

**Comparison of preoperative FNAC and CNB diagnostic categories**

Of the 104 cases, 66 cases were re-examined with thyroid CNB before surgical resection. They were initially categorized as non-diagnostic (n = 15), benign (n = 3), AUS (n = 47), and SFN

| FNAC diagnostic category | No. of surgical specimens | Final diagnosis |
|--------------------------|---------------------------|-----------------|
| I. Non-diagnostic        | 18 (17.3%)                | FA 9 (21.4%) FTC 4 (9.5%) HA 3 (12.5%) HC 0 (0%) |
| II. Benign               | 13 (12.5%)                | 3 (18.2%) FTC 4 (16.7%) HA 6 (46.2%) HC 4 (66.7%) |
| III. AUS                 | 63 (60.6%)                | 25 (59.5%) FTC 14 (58.3%) HA 20 (62.5%) HC 4 (66.7%) |
| AUS-Ca                   | 19 (18.3%)                | 9 (21.4%) FTC 4 (16.7%) HA 6 (18.8%) HC 0 (0%) |
| AUS-CA                   | 21 (20.2%)                | 12 (28.6%) FTC 8 (33.3%) HA 1 (3.1%) HC 0 (0%) |
| AUS-CA and AA            | 4 (3.8%)                  | 2 (4.8%) FTC 2 (8.3%) HA 0 (0%) HC 0 (0%) |
| AUS-H                    | 19 (18.3%)                | 2 (4.8%) FTC 0 (0%) HA 13 (40.6%) HC 4 (66.7%) |
| IV. Suspicious for a FN  | 7 (6.7%)                  | 3 (7.1%) FTC 3 (12.5%) HA 1 (3.1%) HC 0 (0%) |
| V. Suspicious for malignancy | 2 (1.9%)                | FA 1 (2.4%) FTC 0 (0%) HA 0 (0%) HC 1 (16.7%) |
| VI. Malignant            | 1 (1.0%)                  | 0 (0%) FTC 0 (0%) HA 0 (0%) HC 1 (16.7%) |
| Total                    | 104                       | 42 FTC 24 HA 32 HC 6 |

FNAC, fine needle aspiration cytology; AUS, atypia of undetermined significance; CA, cytologic atypia, AA, architectural atypia; H, Hurthle cell; FN, follicular neoplasm; FA, follicular adenoma; FTC, follicular thyroid carcinoma; HA, Hurthle cell adenoma; HC, Hurthle cell carcinoma.
In CNB, 8 (53.3%), 1 (33.3%), and 22 (46.8%) cases with the original FNAC DC I (non-diagnostic), DC II (benign), and DC III (AUS) were diagnosed as CNB DC IV (SFN). After review of original FNAC, 8 (50.0%), 1 (50.0%), and 17 (41.5%) cases with revised FNAC DC I (non-diagnostic), DC II (benign), and DC III (AUS) were diagnosed with DC IV (SFN) in CNB (Fig 5). The frequencies of DCs in the 66 CNB are listed in Table 4. In total, 35 (53.0%) were categorized as indeterminate lesion and 31 (47.0%) were classified as SFN in CNB. There were no cases with non-diagnostic or benign categories. None of the cases were categorized as suspicious for PTC or PTC.

Comparison of cytologic features according to FNAC diagnostic categories

Various cytologic parameters including cellularity, presence of artifact, architectural pattern, nuclear features, and background quality were analyzed in FNAC slides and were compared among cases with different DCs (Table 5). Compared to FNACs with DC II (benign), those with DC IV (SFN) showed a significant association with higher cellularity (p < 0.001). In terms of architectural pattern, predominant microfoliclular pattern, presence of architectural crowding, 3-dimensional branching pattern, microfoliclules arranged in trabecular pattern, and

### Table 3. Summary of the thyroid FNACs with revised diagnosis upon review.

| Case No. | Original diagnosis | Revised diagnosis | Final surgical diagnosis | Reason for revision |
|----------|--------------------|-------------------|--------------------------|--------------------|
| 71       | Benign             | AUS-H             | HA                       | predominantly Hurthle cells, no colloid, architectural alteration |
| 73       | Benign             | AUS-MF            | FTC                      | moderately cellular specimen with abundant microfoliclules |
| 76       | Benign             | Non-diagnostic    | HA                       | less than 60 follicular cells, no colloid |
| 78       | Benign             | AUS-MF            | FA                       | less than 60 follicular cells with predominant microfoliclules, no colloid |
| 99       | Benign             | Non-diagnostic    | FTC                      | less than 60 follicular cells, no colloid |
| 54       | AUS-CA             | SFN               | FA                       | moderately cellular specimen with microfoliclules, trabecular pattern, transgressing vessels |
| 72       | AUS-CA             | SFN               | FA                       | moderately cellular specimen with abundant microfoliclules |
| 86       | AUS-CA             | SFN               | HA                       | less than 60 Hurthle cells with architectural alteration, no colloid |
| 20       | AUS-AA             | SFN               | FA                       | moderately cellular specimen with abundant microfoliclules, transgressing vessels |
| 35       | AUS-AA             | SFN               | FTC                      | moderately cellular specimen with abundant microfoliclules |
| 57       | AUS-AA             | SFN               | FA                       | moderately cellular specimen with abundant microfoliclules, transgressing vessels |
| 61       | AUS-AA             | SFN               | FA                       | moderately cellular specimen with abundant microfoliclules, transgressing vessels |
| 60       | AUS-H              | SFN               | HA                       | moderately cellular specimen with Hurthle cells, large cell dysplasia, architectural alteration, transgressing vessels |
| 67       | AUS-H              | SFN               | HA                       | moderately cellular specimen with Hurthle cells, large cell dysplasia, architectural alteration, transgressing vessels |
| 68       | AUS-H              | SFN               | HA                       | moderately cellular specimen with Hurthle cells, abundant microfoliclules, transgressing vessels |
| 75       | AUS-H              | AUS-CA and AA     | FA                       | barely over 60 follicular cells, focal Hurthle cell change, focal nuclear atypia, microfoliclules |
| 64       | SFN                | AUS-H             | HA                       | moderately cellular specimen with Hurthle cells, predominantly macrofoliclules, focal microfoliclules |
| 50       | s/f PTC            | AUS-CA and AA     | FA                       | moderately cellular specimen with both macro- and microfoliclules, focal nuclear atypia |
| 103      | s/f PTC            | SFN               | HC                       | moderately cellular specimen with Hurthle cells, large cell dysplasia, dissociated cells, trabecular pattern, transgressing vessels |
| 27       | PTC                | AUS-H             | HC                       | less than 60 Hurthle cells, large cell dysplasia, mild architectural alteration |

FNAC, fine needle aspiration cytology; AUS, atypia of undetermined significance; SFN, suspicious for a follicular neoplasm, CA, cytologic atypia, AA, architectural atypia; H, hurthle cell; PTC, papillar thyroid carcinoma; FA, follicular adenoma; FTC, follicular thyroid carcinoma; HA, Hurthle cell adenoma; HC, Hurthle cell carcinoma.

https://doi.org/10.1371/journal.pone.0241597.1003
transgressing vessels were more commonly identified in the specimens with DC IV (SFN) (all p < 0.05). Nuclear enlargement (p = 0.007) was more frequent in the DC IV (SFN) cases while the frequency of anisonucleosis, nuclear hyperchromasia, prominent nucleoli, small cell dysplasia, and large cell dysplasia did not differ between the two groups. In addition, the presence of background colloid, especially watery colloid, was associated with DC II (benign) (p = 0.032) (Table 5).

Compared to those cases with DC III (AUS), cases diagnosed as DC IV (SFN) were associated with higher cellularity, predominant microfollicular pattern, microfollicles arranged in trabecular pattern, and transgressing vessels (all p < 0.05) (Table 5).

**Correlation of FNAC diagnostic categories with histologic features in surgical resection specimens**

We compared histologic features of tumor in the resection specimen among nodules with different FNAC DCs (Table 6). Among the various histologic features including proportion of normo- and macrofollicular pattern, papillary hyperplasia, intratumoral fibrosis, calcification or bony metaplasia, cystic degeneration, hemorrhage, background lymphocytic thyroiditis, and tumor size, only the presence of normo- and macrofollicular pattern in ≥2/3 of the tumoral area was significantly associated with tumors diagnosed as DC II (benign) compared
to those diagnosed as DC IV (SFN) in FNAC (p = 0.028). There were no significant differences in the other histologic variables between DC II (benign) and DC IV (SFN) or DC III (AUS) and DC IV (SFN) (Table 6).

**Comparison of cytologic features of histologically proven benign and malignant neoplasm**

We also compared the cytologic parameters of nodules with the final surgical diagnoses of benign and malignant tumors (Table 7). FNACs of FTC were more cellular (p<0.001) and
more commonly showed microfollicle arranged in trabecular pattern \( p = 0.042 \) than FA.

Compared with HAs, prominent nucleoli \( p = 0.001 \) and large cell dysplasia \( p = 0.007 \) were observed more often in HCs.

**Discussion**

The DC IV (SFN) in TBSRTC had been referred to various terminologies, including “follicular lesion”, “follicular proliferation”, “SFN”, or “FN” prior to implementation of TBSRTC [25–29]. This reflects the difficulty in differentiating FACHACs from other follicular proliferative lesions such as cellular adenomatoid nodule, follicular variant of PTC, and NIFTP by FNAC alone due to their similar cytologic features [3–5]. The goal of designating TBSRTC DC IV (SFN) is not to seek out all FACHACs but to identify those thyroid nodules with malignant potential. Currently, TBSRTC DC IV (SFN) is recommended for nodules that are at least moderately cellular and show prominent architectural alteration including cellular crowding, microfollicles, and dispersed isolated cells [1, 2]. Nevertheless, many researchers have reported poor cytohistologic correlation of DC IV (SFN) [22, 27, 30–33]. Up to 44% of the nodules of which the cytologic features were concordant with DC IV (SFN), turned out to be non-neoplastic lesions [27], implying that diagnosing follicular-patterned neoplasms remains challenging.

In our institution, DC IV (SFN) constituted only 0.8% of all FNAC cases diagnosed between 2012 and 2014 [34]. Considering the much lower incidence of FTC as opposed to PTC in Korea compared to western countries, the diagnostic rate of DC IV (SFN) can be assumed to be low in Korea. We tried to uncover whether there are other reasons for low rate of DC IV (SFN) than low incidence of FTC in our institute.

In the present study, 20 out of 104 cases were re-categorized after a thorough review of the FNAC slides. A total of 3 cases-1 FA and 2 HCs- were originally misdiagnosed as suspicious for PTC or PTC. Overestimation of mild nuclear atypia, especially in Hurthle cells, was the main cause of these misdiagnoses. The extremely low incidence of HNs compared with PTC in our institution might have affected the misdiagnoses as well. Although nuclear grooves, intranuclear inclusions, and even slight chromatin clearing can be seen in HNs, nuclei are generally round with prominent nucleoli [35–37]. Therefore, cytopathologists should always be
aware of this pitfall and be careful not to misdiagnose HNs as PTC since treatment options including lymph node dissection and prognosis can be different in these two diseases [38, 39].

Of the 11 cases with DC III (AUS) in original FNAC diagnoses, 9 cases fulfilled the criteria of DC IV (SFN). 3 out of 5 cases with the original DC II (benign) were consistent with DC III (AUS). This under-diagnosis might have resulted from some confounding factors such as the pathologist’s reluctance in diagnosing DC IV (SFN) due to fear of diagnostic lobectomy and lack of experience in thyroid cytopathology. Although we have revised DCs in 20 cases, over

| Cytological features                              | Benign | AUS     | SFN     | P-value<sup>a</sup> | P-value<sup>b</sup> |
|---------------------------------------------------|--------|---------|---------|----------------------|----------------------|
| Cellularity                                        |        |         |         |                      |                      |
| <60                                                | 6 (75.0%) | 17 (28.3%) | 0 (0%) | <0.001               | 0.008*               |
| Barely over 60                                     | 2 (25.0%) | 19 (31.7%) | 3 (18.8%) |                      |                      |
| Moderately to markedly cellular                    | 0 (0%) | 24 (40.0%) | 13 (81.3%) |                      |                      |
| Artifact (drying, clotting, etc.)                  | 3 (37.5%) | 42 (70.0%) | 10 (62.5%) | 0.390               | 0.566               |
| Macrofollicle                                      |        |         |         | <0.001               | <0.001               |
| None to focal                                      | 2 (25.0%) | 53 (88.3%) | 16 (100.0%) |                      |                      |
| Predominant                                        | 6 (75.0%) | 7 (11.7%) | 0 (0%) |                      |                      |
| Microfollicle                                      |        |         |         | 0.001               | 0.002               |
| None to focal                                      | 8 (100.0%) | 42 (70.0%) | 4 (25.0%) |                      |                      |
| Predominant                                        | 0 (0%) | 18 (30.0%) | 12 (75.0%) |                      |                      |
| Microfollicles arranged in trabecular pattern      |        |         |         |                      |                      |
| None to focal                                      | 0 (0%) | 12 (20%) | 8 (50.0%) | 0.022               | 0.015               |
| Predominant                                        |        |         |         |                      |                      |
| Architectural crowding                             | 3 (37.5%) | 59 (98.3%) | 16 (100.0%) | 0.001               | 1.000               |
| 3-dimensional branching                            | 2 (25.0%) | 42 (70.0%) | 15 (93.8%) | 0.001               | 0.585               |
| Trabecular or solid pattern                        | 0 (0%) | 2 (3.3%) | 3 (18.75%) | 0.532               | 0.081               |
| Transgressing vessels                              | 1 (12.5%) | 12 (20.0%) | 11 (68.8%) | 0.027               | <0.001               |
| Nuclear enlargement                                | 3 (37.5%) | 57 (95.0%) | 15 (93.8%) | 0.007               | 1.000               |
| Anisonucleosis                                     | 4 (50.0%) | 46 (76.7%) | 9 (56.3%) | 1.000               | 0.105               |
| Nuclear hyperchromasia                             | 2 (25.0%) | 21 (35.0%) | 5 (31.3%) | 1.000               | 0.779               |
| Prominent nucleoli                                 | 0 (0%) | 11 (18.3%) | 4 (25.0%) | 0.262               | 0.724               |
| Small cell dysplasia                               | 0 (0%) | 1 (1.7%) | 0 (0%) | 1.000               | 1.000               |
| Large cell dysplasia                               | 0 (0%) | 8 (13.3%) | 4 (25.0%) | 0.262               | 0.265               |
| Nuclear chromatin clearing                         | 0 (0%) | 25 (41.7%) | 8 (50.0%) | 0.022               | 0.55                |
| Nuclear groove                                     | 1 (12.5%) | 39 (65.0%) | 8 (50.0%) | 0.178               | 0.272               |
| Nuclear inclusion mimicker                         | 0 (0%) | 5 (8.3%) | 0 (0%) | 1.000               | 0.578               |
| Blood                                              | 4 (50.0%) | 34 (56.7%) | 9 (56.3%) | 1.000               | 1.000               |
| Cystic change                                      | 1 (12.5%) | 9 (15.0%) | 0 (0%) | 0.333               | 0.191               |
| Colloid                                            | 0.032 | 0.359 |               |                      |                      |
| Absent                                             | 3 (37.5%) | 46 (76.7%) | 10 (62.5%) |                      |                      |
| Thin colloid                                       | 3 (37.5%) | 1 (1.7%) | 0 (0%) |                      |                      |
| Thick colloid                                      | 2 (25.0%) | 11 (18.3%) | 6 (37.5%) |                      |                      |
| Thin and thick colloid                             | 0 (0%) | 2 (3.3%) | 0 (0%) |                      |                      |
| Colloid quantity                                   |        |         |         | 0.080               | 0.521               |
| Focal                                              | 1 (12.5%) | 13 (21.7%) | 5 (31.3%) |                      |                      |
| Prominent                                          | 4 (50.0%) | 1 (1.7%) | 1 (6.3%) |                      |                      |
| Total                                              | 8 | 60 | 16 |                      |                      |

AUS, atypia of undetermined significance; SFN, suspicious for a follicular neoplasm.

<sup>a</sup> Benign vs. SFN  
<sup>b</sup> AUS vs. SFN.

https://doi.org/10.1371/journal.pone.0241597.t005
half of DC I (non-diagnostic) cases in FNAC were categorized as DC IV (SFN) in CNB, suggesting problems in specimen inadequacy of FNAC specimens. Moreover, significant proportions of DC II (benign) and DC III (AUS) cases were diagnosed as DC IV in CNB, suggesting under-diagnosis in FNAC. The advantage of CNB over FNAC in diagnosing FNs has also been demonstrated by other researchers, and it might be due to the fact that thyroid CNB not only reveals the nodule itself but also its histologic relationship with the capsule and adjacent normal thyroid tissue [13–15]. This suggests that thyroid CNB can be useful primary or complementary tool when FACHAC is suspected clinically or radiologically.

Apart from the innate disadvantage of FNAC in diagnosing FACHAC as opposed to CNB, we further analyzed diverse cytomorphologic and histologic parameters of each nodule, and we investigated the differences between the groups with DC II (benign), III (AUS) and IV (SFN) in FNAC to identify other possible reasons for under-diagnosis. When we analyzed the cytologic parameters, the cases that had been underdiagnosed were far less cellular than those with DC IV(SFN), reflecting the significance of acquiring a proper FNAC specimen with sufficient cellularity. In addition, a predominantly macrofollicular pattern and the presence of thin colloid were associated with under-diagnosis. Similarly, a predominant normo- or macrofollicular pattern in surgically resected specimens was associated with under-diagnosis. Our result is in line with previous studies which have demonstrated that macrofollicular variant of FAs and FTCs can mimic nodular hyperplasia and are generally underappreciated in FNAC [4, 40–42]. Bongiovanni et al. have recently described the presence of pathogenic somatic mutations in DICER1, EIF1AX, and DNMT3A genes in four cases of macrofollicular variant of FTC, suggesting that additional molecular testing can be helpful in a clinically malignant nodule with deceptively benign FNAC findings [40]. Further investigations are warranted to determine whether a certain mutation is more common in macrofollicular variant of FTC.

Finally, we compared the cytologic features between the nodules finally diagnosed as benign versus malignant neoplasm (FA versus FTC, and HA versus HC). Compared with FAs, FTCs were significantly more hypercellular. Although controversial, cellularity has been proposed as one of the distinguishing features of malignancy in some studies [43, 44]. Of note, microfollicles were sometimes arranged in trabecular or branching pattern, which was more frequently

---

| Histologic features                          | Benign | AUS | SFN | P-value* | P-valueb |
|---------------------------------------------|--------|-----|-----|----------|----------|
| Normo-macrofollicular pattern ≥2/3          | 3 (37.5%) | 5 (8.3%) | 0 (0%) | 0.028 | 0.578 |
| Papillary hyperplasia                       | 1 (12.5%) | 3 (5.0%) | 2 (13.3%) | 1.000 | 0.282 |
| Intratumoral fibrosis                       | 2 (25.0%) | 33 (55.0%) | 6 (40.0%) | 0.667 | 0.191 |
| Calcification or bony metaplasia            | 1 (12.5%) | 3 (5.0%) | 0 (0%) | 0.333 | 1.000 |
| Cystic degeneration                         | 2 (28.6%) | 17 (28.3%) | 4 (26.7%) | 1.000 | 1.000 |
| Background lymphocytic thyroiditis          | 2 (28.6%) | 8 (13.3%) | 4 (26.7%) | 1.000 | 0.265 |
| Size of tumor, median (range, cm)           | 1.0 (0.5–5.2) | 2.3 (0.6–6.5) | 2.4 (0.9–5.5) | 0.238 | 0.954 |
| Low                                        | 1 (14.3%) | 11 (18.3%) | 0 (0%) | 0.128 | 0.092 |
| Indeterminate                               | 6 (85.7%) | 38 (63.3%) | 15 (100.0%) | 0.667 | 0.191 |
| Suspicious                                  | 1 (14.3%) | 2 (3.3%) | 0 (0%) | 0.333 | 1.000 |
| NA                                         | 0 (0%) | 9 (15%) | 1 (6.7%) | 0.028 | 0.578 |
| Total                                       | 8 | 60 | 16 | 0.578 | 0.282 |

AUS, atypia of undetermined significance; SFN, suspicious for a follicular neoplasm; USG, ultrasonography.

*Benign vs. SFN
bAUS vs. SFN.

https://doi.org/10.1371/journal.pone.0241597.t006
identified in FTCs (40.0%) than FAs (15.2%). Han et al. have also described that this trabecular pattern was more commonly observed in FAs and FTCs than in nodular hyperplasia although the frequency did not differ between FAs and FTCs [22]. Further evaluation in a larger cohort is required to elucidate the significance of this unique pattern. Other cytologic parameters reported to be associated with malignancy include absence of thin colloid, absence of macrofolicular pattern, crowding, high nuclear-cytoplasmic ratio, nuclear atypia, and transgressing vessels [43–46], which were not found to be significantly different between the two groups.

Table 7. Comparison of cytological features between histologically proven benign and malignant neoplasms.

| Cytological features                              | FA     | FTC    | HA     | HC     | P-value<sup>a</sup> | P-value<sup>b</sup> |
|---------------------------------------------------|--------|--------|--------|--------|----------------------|----------------------|
| Cellularity                                        |        |        |        |        | <0.001               | 0.168                |
| <60                                                | 10 (30.3%) | 8 (40.0%) | 4 (16.0%) | 1 (16.7%) |                      |                      |
| Barely over 60                                     | 10 (30.3%) | 1 (5.0%) | 11 (44.0%) | 2 (33.3%) |                      |                      |
| Moderately cellular                                | 13 (39.4%) | 11 (55.0%) | 10 (40.0%) | 3 (30.0%) |                      |                      |
| Artifact (drying, clotting, etc.)                  | 20 (60.6%) | 11 (55.0%) | 20 (80.0%) | 4 (66.7%) | 0.688                | 0.596                |
| Macrofollicle                                      |        |        |        |        | 0.457                | 0.553                |
| None to focal                                      | 29 (87.9%) | 16 (80.0%) | 20 (80.0%) | 6 (100.0%) |                      |                      |
| Predominant                                        | 4 (12.1%) | 4 (20.0%) | 5 (20.0%) | 0 (0%) |                      |                      |
| Microfollicle                                      |        |        |        |        | 0.374                | 0.553                |
| None to focal                                      | 19 (57.6%) | 9 (45.0%) | 20 (80.0%) | 6 (100.0%) |                      |                      |
| Predominant                                        | 14 (42.4%) | 11 (55.0%) | 5 (20.0%) | 0 (0%) |                      |                      |
| Microfollicle arranged in trabecular pattern       | 5 (15.2%) | 8 (40.0%) | 4 (16.0%) | 1 (16.7%) | 0.042                | 1.000                |
| Architectural crowding                             | 30 (90.9%) | 18 (90.0%) | 24 (96.0%) | 6 (100.0%) | 1.000                | 1.000                |
| 3-dimensional branching                            | 22 (66.7%) | 13 (65.0%) | 19 (76.0%) | 5 (83.3%) | 0.901                | 1.000                |
| Trabecular or solid pattern                        | 1 (3.0%) | 0 (0%) | 3 (12.0%) | 1 (16.7%) | 1.000                | 1.000                |
| Transgressing vessels                              | 8 (24.2%) | 2 (10.0%) | 12 (48.0%) | 2 (33.3%) | 0.286                | 0.664                |
| Nuclear enlargement                                | 27 (81.8%) | 17 (85.0%) | 25 (100.0%) | 6 (100.0%) | 0.767                | 1.000                |
| Anisonucleosis                                     | 20 (60.6%) | 11 (55.0%) | 22 (88.0%) | 6 (100.0%) | 0.688                | 1.000                |
| Nuclear hyperchromasia                             | 3 (9.1%) | 5 (25.0%) | 14 (56.0%) | 6 (100.0%) | 0.137                | 0.066                |
| Prominent nucleoli                                 | 1 (3.0%) | 3 (15.0%) | 5 (20.0%) | 6 (100.0%) | 0.145                | 0.001                |
| Small cell dysplasia                               | NE     | NE     | 1 (4%) | 0 (0%) | -                    | 1.000                |
| Large cell dysplasia                               | NE     | NE     | 5 (20.0%) | 5 (83.3%) | -                    | 0.007                |
| Nuclear chromatin clearing                         | 17 (51.5%) | 8 (40.0%) | 5 (20.0%) | 1 (16.7%) | 0.416                | 1.000                |
| Nuclear grove                                       | 20 (60.6%) | 11 (55.0%) | 14 (56.0%) | 3 (50.0%) | 0.688                | 1.000                |
| Nuclear inclusion mimicker                         | 2 (6.1%) | 0 (0%) | 2 (8.0%) | 1 (16.7%) | 0.521                | 0.488                |
| Blood                                              | 18 (54.5%) | 7 (35.0%) | 18 (72.0%) | 4 (66.7%) | 0.167                | 1.000                |
| Cystic change                                       | 3 (9.1%) | 1 (5.0%) | 4 (16.0%) | 2 (33.3%) | 1.000                | 0.567                |
| Colloid                                            |        |        |        |        | 0.446                | 0.315                |
| Absent                                             | 24 (72.7%) | 14 (70.0%) | 15 (60.0%) | 6 (100.0%) |                      |                      |
| Thin colloid                                       | 2 (6.1%) | 0 (0%) | 2 (8.0%) | 0 (0%) |                      |                      |
| Thick colloid                                      | 7 (21.2%) | 6 (30.0%) | 6 (24.0%) | 0 (0%) |                      |                      |
| Thin and thick colloid                             | 0 (0%) | 0 (0%) | 2 (8.0%) | 0 (0%) |                      |                      |
| Colloid quantity                                   |        |        |        |        | 1.000                | -                    |
| Focal                                              | 8 (24.2%) | 5 (25.0%) | 8 (32.0%) | NE |                      |                      |
| Prominent                                          | 1 (3.0%) | 1 (5.0%) | 2 (8.0%) | NE |                      |                      |
| Total                                              | 33     | 20     | 25     | 6 |                      |                      |

FA, follicular adenoma; FTC, follicular thyroid carcinoma; HA, Hurthle cell adenoma; HC, Hurthle cell carcinoma; NE, not evaluable.

<sup>a</sup>FA vs. FTC

<sup>b</sup>HA vs. HC.

https://doi.org/10.1371/journal.pone.0241597.T007
Recently, Gupta et al. [47] and Savala et al. [48] applied artificial neural network models and gray level co-occurrence of matrix method to analyze basic cytomorphological features and they reported promising results suggesting that objective measurement can be a solution to more accurate diagnosis.

When comparing HCs with HAs, HCs more frequently showed prominent nucleoli and large cell dysplasia. Similarly, Renshaw et al. have suggested that the presence of at least one of small cell dysplasia, large cell dysplasia, crowding, or dyshesion favors malignancy [23, 49]. In addition, four characteristic cytologic features of HCs including syncytial fragments, small sized cells with high nucleo-cytoplasmic ratio, prominent nucleoli, and intranuclear inclusions have been described [45]. Although others have disputed consistency, these morphologic criteria combined with clinical parameters and recently developed molecular testing may be helpful for accurate triage of HNs [50, 51].

Interestingly, we identified transgressing vessels not only in HNs but also in conventional FAs and FTCs although the frequency did not significantly differ between FAs and FTCs. The presence of transgressing vessels has been a traditional parameter that favors HNs over non-neoplastic Hurthle cell proliferative lesions associated with lymphocytic thyroiditis or Graves’ disease [29, 36, 45, 52]. Lubitz et al. have described this structure in FAs and FTCs in addition to HNs and reported that the presence of transgressing vessels was associated with malignancy [43]. Unfortunately, we were unable to elucidate the association of transgressing vessels with neoplasm, because we did not include non-neoplastic lesions in the current study. Further investigation including non-neoplastic lesion would be needed.

In the present study, we performed a systematic and comprehensive investigation of fundamental cytomorphologic and histologic parameters of histologically proven FACHACs. We observed that there was a significant number of mis- or underdiagnoses in preoperative FNAC of FACHAC. Overestimation of the subtle nuclear atypia was responsible for most of the mis-diagnoses. As for underdiagnoses, the innate cytohistologic features as well as inadequate sampling were the leading causes. Of note, we identified some cytologic features associated with malignancy. Since application of recently developed molecular testing and artificial intelligence are not feasible in routine practice at most institutions, understanding the basic cytologic features along with complementary CNB should improve the diagnostic accuracy of FACHAC in FNAC.

**Conclusions**

In conclusion, it is not only the low incidence, but also the sample quality and innate cytohistologic features of a tumor that are associated with under-interpretation of FACHAC in FNAC. To improve sensitivity and specificity, acquiring a proper sample is a prerequisite along with cautious interpretation of basic cytologic features including nuclear atypia. Higher cellularity, the presence of microfollicles arranged in trabecular pattern, nucleolar prominence, and the presence of large cell dysplasia can be helpful in differentiating FTC or HC from FA or HA.

**Supporting information**

S1 Data. Summary of cytologic and histologic features of follicular adenoma and carcinoma, Hurthle cell adenoma and carcinoma included in this study.

(XLSX)

**Acknowledgments**

We are indebted to Dr. Yul Ri Chung for editing the manuscript.
Author Contributions

Conceptualization: Hee Young Na, So Yeon Park.

Data curation: Hee Young Na, Ji-Young Choe.

Formal analysis: Hee Young Na.

Investigation: Hee Young Na, Jae Hoon Moon, June Young Choi, Hyeong Won Yu, Woo-Jin Jeong, Yeo Koon Kim, Ji-Young Choe.

Methodology: Hee Young Na, Jae Hoon Moon, June Young Choi, Hyeong Won Yu, Woo-Jin Jeong, Yeo Koon Kim, Ji-Young Choe.

Resources: Jae Hoon Moon, June Young Choi, Hyeong Won Yu, Woo-Jin Jeong, Yeo Koon Kim, Ji-Young Choe.

Supervision: So Yeon Park.

Validation: Hee Young Na, So Yeon Park.

Writing – original draft: Hee Young Na.

Writing – review & editing: Jae Hoon Moon, June Young Choi, Hyeong Won Yu, Woo-Jin Jeong, Yeo Koon Kim, Ji-Young Choe, So Yeon Park.

References

1. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2009; 19(11):1159–65. https://doi.org/10.1089/thy.2009.0274 PMID: 19888858

2. Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid. 2017; 27(11):1341–6. https://doi.org/10.1089/thy.2017.2900 PMID: 29091573

3. Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002; 117(1):143–50. https://doi.org/10.1309/8VL9-ECXY-NVMX-2RQF PMID: 11789719

4. Kini SR, Miller JM, Hamburger JI, Smith-Purslow MJ. Cytopathology of follicular lesions of the thyroid gland. Diagn Cytopathol. 1985; 1(2):123–32. https://doi.org/10.1002/dc.2840010208 PMID: 3841772

5. Zacks JF, de las Morenas A, Beazley RM, O’Brien MJ. Fine-needle aspiration cytology diagnosis of colloid nodule versus follicular variant of papillary carcinoma of the thyroid. Diagn Cytopathol. 1998; 18(2):87–90. https://doi.org/10.1002/(sici)1097-0339(199802)18:2<87::aid-dc1>3.0.co;2-q PMID: 9484634

6. Park S, Oh CM, Cho H, Lee JY, Jung KW, Jun JK, et al. Association between screening and the thyroid cancer “epidemic” in South Korea: evidence from a nationwide study. BMJ. 2016; 355:i5745. https://doi.org/10.1136/bmj.i5745 PMID: 27903497

7. Aschebrook-Kilfoy B, Grogan RH, Ward MH, Kaplan E, Devesa SS. Follicular thyroid cancer incidence patterns in the United States, 1980–2009. Thyroid. 2013; 23(8):1015–21. https://doi.org/10.1089/thy.2012.0356 PMID: 23360496

8. Dal Maso L, Lise M, Zambon P, Falcini F, Crocetti E, Serraino D, et al. Incidence of thyroid cancer in Italy, 1991–2005: time trends and age-period-cohort effects. Ann Oncol. 2011; 22(4):957–63. https://doi.org/10.1093/annonc/mdq467 PMID: 20952599

9. Anderson TJ, Atalay MK, Grand DJ, Baird GL, Cronan JJ, Beland MD. Management of nodules with initially nondiagnostic results of thyroid fine-needle aspiration: can we avoid repeat biopsy? Radiology. 2014; 272(3):777–84. https://doi.org/10.1148/radiol.14132134 PMID: 24749714

10. Choe JY, Kwak Y, Kim M, Chung YR, Kim HJ, Kim YK, et al. Utility of a formatted pathologic reporting system in thyroid core needle biopsy: A validation study of 1998 consecutive cases. Clin Endocrinol (Oxf). 2018; 88(1):96–104. https://doi.org/10.1111/cen.13397 PMID: 28618022

11. Hahn SY, Shin JH, Han BK, Ko EY, Ko ES. Ultrasonography-guided core needle biopsy for the thyroid nodule: does the procedure hold any benefit for the diagnosis when fine-needle aspiration cytology analysis shows inconclusive results? Br J Radial. 2013; 86(1025):20130007. https://doi.org/10.1259/ bj/20130007 PMID: 23964885

12. Na DG, Kim JH, Sung JY, Baek JH, Jung KC, Lee H, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined
significance by the Bethesda system for reporting thyroid cytopathology. Thyroid. 2012; 22(5):468–75. https://doi.org/10.1089/thy.2011.0185 PMID: 22304417

13. Min HS, Kim JH, Ryoo I, Jung SL, Jung CK. The role of core needle biopsy in the preoperative diagnosis of follicular neoplasm of the thyroid. APMS. 2014; 122(10):993–1000. https://doi.org/10.1111/apm. 12244 PMID: 24673498

14. Nasrollah N, Trimbori P, Guidobaldi L, Ciccarella Modica DV, Ventura C, Ramacciato G, et al. Thin core biopsy should help to discriminate thyroid nodules cytologically classified as indeterminate. A new sampling technique. Endocrine. 2013; 43(3):659–65. https://doi.org/10.1007/s12020-012-9811-z PMID: 23070753

15. Yoon RG, Baek JH, Lee JH, Choi YJ, Hong MJ, Song DE, et al. Diagnosis of thyroid follicular neoplasm: fine-needle aspiration versus core-needle biopsy. Thyroid. 2014; 24(11):1612–7. https://doi.org/10. 1089/thy.2014.0140 PMID: 25089716

16. Kim M, Park HJ, Min HS, Kwon HJ, Chae SW, et al. The Use of the Bethesda System for Reporting Thyroid Cytopathology in Korea: A Nationwide Multicenter Survey by the Korean Society of Endocrine Pathologists. J Pathol Transl Med. 2017; 51(4):410–7. https://doi.org/10.4132/jptm.2017.04. 05 PMID: 28609825

17. Bongiovanni M, Spitali A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda System for Reporting Thyroid Cytopathology: a meta-analysis. Acta Cytol. 2012; 56(4):333–9. https://doi.org/10.1159/ 000339959 PMID: 22846242

18. Lloyd RV, Osamura RY, Klöppel G, Rosai J. WHO classification of tumours of endocrine organs. 4th ed. Lyon: IARC Press; 2017.

19. Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo F, Thompson LD, et al. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors. JAMA Oncol. 2016; 2(8):1023–9. https://doi.org/10.1001/jamaoncol. 2016.0386 PMID: 27078145

20. Puxeddu E, Filetti S. The 2009 American Thyroid Association Guidelines for management of thyroid nodules and differentiated thyroid cancer: progress on the road from consensus- to evidence-based practice. Thyroid. 2009; 19(11):1145–7.

21. Moon WJ, Baek JH, Jung SL, Kim DW, Kim EK, Kim JY, et al. Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol. 2011; 12(1):1–14. https://doi.org/10.3348/kjr.2011.12.1.1 PMID: 21228935

22. Han K, Ha HJ, Kong JS, Kim JS, Myung JK, Koh JS, et al. Cytological Features That Differentiate Follicular Neoplasm from Mimicking Lesions. J Pathol Transl Med. 2018; 52(2):110–20. https://doi.org/10. 4132/jptm.2018.01.17 PMID: 29374960

23. Renshaw AA. Hurthle cell carcinoma is a better gold standard than Hurthle cell neoplasm for fine-needle aspiration of the thyroid: defining more consistent and specific cytologic criteria. Cancer. 2002; 96 (5):261–6. https://doi.org/10.1002/cncr.10797 PMID: 12378592

24. Jung CK, Min HS, Park HJ, Song DE, Kim JH, Park SY, et al. Pathology Reporting of Thyroid Core Needle Biopsy: A Proposal of the Korean Core Endocrine Pathology Thyroid Core Needle Biopsy Study Group. J Pathol Transl Med. 2015; 48(4):288–99. https://doi.org/10.4132/jptm.2015.06.04 PMID: 26081825

25. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol. 2002; 26(1):41–4. https://doi.org/10.1002/dc.10043 PMID: 11782086

26. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 1993; 118(4):282–9. https://doi.org/10.7326/0003-4819-118-4-199302150-00007 PMID: 8420446

27. Greaves TS, Olvera M, Florentine BD, Raza AS, Cobb CJ, Tsao-Wei DD, et al. Follicular lesions of the thyroid: a 5-year fine-needle aspiration experience. Cancer. 2000; 90(6):335–41. PMID: 11156516

28. Wang HH. Reporting thyroid fine-needle aspiration: literature review and a proposal. Diagn Cytopathol. 2006; 34(1):67–76. https://doi.org/10.1002/dc.20400 PMID: 16355378

29. Yang GC, Liebeskind D, Messina AV. Should cytopathologists stop reporting follicular neoplasms on fine-needle aspiration of the thyroid? Cancer. 2003; 99(2):69–74. https://doi.org/10.1002/cncr.10957 PMID: 12704685

30. Deveci MS, Deveci G, LiVolsi VA, Baloch ZW. Fine-needle aspiration biopsy of follicular lesions of the thyroid. Diagnosis and follow-Up. Cytojournal. 2006; 3:9. https://doi.org/10.1186/1742-6413-3-9 PMID: 16603062

31. Faquin WC. Diagnosis and reporting of follicular-patterned thyroid lesions by fine needle aspiration. Head Neck Pathol. 2009; 3(1):82–5. https://doi.org/10.1007/s12105-009-0104-7 PMID: 20596996

32. Wu HH, Rose C, Elsheikh TM. The Bethesda system for reporting thyroid cytopathology: An experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy. Diagn Cytopathol. 2012; 40(5):399–403. https://doi.org/10.1002/dc.21754 PMID: 21681976
52. Galera-Davidson H. Diagnostic problems in thyroid FNAs. Diagn Cytopathol. 1997; 17(6):422–8. https://doi.org/10.1002/(sici)1097-0339(199712)17:6<422::aid-dc9>3.0.co;2-a PMID: 9407202